| Aug 7 |
Indaptus stock dips on $3M securities offering
|
| Aug 7 |
Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement
|
| Jun 4 |
Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference
|
| Jun 3 |
Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20
|
| May 29 |
Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting
|
| May 22 |
Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors
|
